CAJ | 학술논문

最近几年食管癌治疗方式可选择性逐渐增加,手术仍是早期食管癌主要治疗手段,术前新辅助治疗、术后辅助治疗已逐渐成为可手术食管癌综合治疗的重要组成部分.根治性同期化放疔有可能代替单纯手术作为可手术食管癌治疗的选择.顺铂联合氟尿嘧啶仍是可手术食管癌手术前后辅助治疗的基本方案;新的细胞毒药物如紫杉醇类、拓扑异构酶抑制剂及新联合方案是围手术期治疗研究的热点.
최근궤년식관암치료방식가선택성축점증가,수술잉시조기식관암주요치료수단,술전신보조치료、술후보조치료이축점성위가수술식관암종합치료적중요조성부분.근치성동기화방정유가능대체단순수술작위가수술식관암치료적선택.순박연합불뇨밀정잉시가수술식관암수술전후보조치료적기본방안;신적세포독약물여자삼순류、탁복이구매억제제급신연합방안시위수술기치료연구적열점.
In recent years, there has been a gradual increase in treatment options for patients with esophageal cancer. While surgery remains to be the primary treatment, neoadjuvant and adjuvant therapy, both preoperatively and postoperatively, have become more important in the multidisciplinary treatment of resectable esophageal cancer. Definitive concomitant chemo-radiotherapy may replace surgery as the primary treatment for resectable esophageal cancer. Cisplatin combined with 5-fluorouracil remains the backbone regimen for neoadjuvant and adjuvant therapy. Intense researches are underway to investigate new cytotoxic drugs such as taxanes and topoisomerase inhibitor, and new regimens for perioperative treatment of resectable esophageal cancer.